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The primary aim of this project was to perform a systematic review and meta-analysis of the currently 
available literature, comparing the effectiveness and safety of inpatient versus extended venous 
thromboembolism (VTE) prophylaxis with heparin following major open abdominal or pelvic surgery for 
malignancy. A secondary aim was to use the results of this review to evaluate the economic 
implications of providing extended pharmacological VTE prophylaxis in this population. 
 
A protocol for a systematic review of the literature was first developed, registered and published. 
Systematic literature review and meta-analysis were then performed in accordance with the protocol, 
and the results published. Finally, the results of the literature review were compared to literature 
estimates of the incidence and cost of VTE events in the absence of pharmacological prophylaxis, and 
current cost of Enoxaparin on the Pharmaceutical Benefits Scheme (PBS) in Australia, and a further 
manuscript produced which is currently submitted for consideration of publication.   
 
The result of the literature review was that no significant difference was found in either postoperative 
VTE rates or bleeding complications when comparing patients receiving extended duration versus 
inpatient only heparin VTE prophylaxis following major open abdominopelvic surgery for malignancy.  
However, the available contemporaneously published evidence was limited and of poor quality so this 
finding must be interpreted with caution.  
 
Regarding the secondary aim, cost analysis based on results of the literature review found the cost of 
providing extended duration heparin VTE prophylaxis to be less than that of treating predicted VTE 
events without prophylaxis, and therefore financially justifiable. However, if the initial finding of no 
significant difference in postoperative VTE events with extended compared to inpatient prophylaxis is 
assumed to be correct, on a purely financial basis inpatient only duration prophylaxis may be a more 
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MAIN BODY CHAPTER 1: CONTEXTUAL STATEMENT  
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VTE is a not only a common postoperative complication, but also a significant cause of morbidity and 
mortality1 in surgical patients leading to an associated burden on the healthcare system. Consequently, 
it is important that all reasonable steps are taken to minimise patients’ risk of developing VTE 
postoperatively, to both optimise individual patient’s outcomes and minimise unnecessary expenditure 
on a preventable disease in a healthcare system which has an ultimately finite supply of resources.  
Prophylactic treatments for VTE are widely used, however optimum duration of prophylaxis remains 
unknown as yet. Despite this, extended duration treatment is being increasingly used in many patient 
populations.  
 
The following commentary provides the reader with the background context to the project, reviewing the 
established field of knowledge and current literature regarding VTE, current prophylactic treatments of 
VTE and the relationship to the aims of the project.  
 
Pathophysiology of VTE 
 
The pathophysiology of VTE can be considered in two parts; thrombus formation (Deep vein 
thrombosis or DVT), and subsequent embolisation of the thrombus.  
 
Thrombus is defined as “a structured, solid mass composed of blood constituents that forms in the 
cardiovascular system”2. Formation of DVT in the postoperative patient is usually precipitated by the 
classic “Virchow’s triad” of hypercoagulability (increased predisposition of the blood to coagulation, 
particularly as a result of systematic inflammatory response postoperatively), venous stasis (altered or 
reduced flow of blood through the vessel compared to normal), and local trauma (damage) to vessels, 
which activates the blood’s coagulation cascade via both its extrinsic and intrinsic pathways. 
 
Virchow’s Triad & DVT formation 
 
When intact, the endothelium (innermost lining) of the vessels works to prevent coagulation by both 
preventing platelets from contacting collagen and Von Willebrand factor which trigger them to 
aggregate and degranulate, and by itself producing prostacyclin and nitric oxide which prevent the 
platelets from adhering to the endothelium and aggregating.  It also produces heparin like molecules 
and plasminogen activators which inhibit the coagulation cascade, and thrombomodulin on the 
endothelial surface binds to any locally formed thrombin with the resultant thrombin-thrombomodulin 
complex initiating the anticoagulant proteins C & S2,3.  
 
However, when the endothelium is damaged or dysfunctional as a result of trauma or inflammation 
(such as in the postoperative state), or there is stasis or slowed flow of blood though the vessel, 
platelets in the blood are exposed to collagen and Von Willebrand Factor and bind to these by their 
surface glycoprotein Ia and Ib receptors. Having bound to these, the adherent platelets undergo a 
shape change, aggregate and degranulate (exocytosis of the platelet’s cytoplasmic granules), releasing 
adenosine diphosphate (ADP), thromboxane A2, and producing prostaglandin as well as expressing 
glycoprotein complex IIb-IIIA and multiple coagulation factors collectively referred to as platelet factor 3. 




The ADP, thromboxane and prostaglandin contribute to the development of a “platelet plug” by 
stimulating further aggregation and adhesion of other platelets, creating a positive feedback loop. The 
release of prostaglandin also causes vasoconstriction of the vessel involved and hence further 
reduction in blood flow. The expression of glycoprotein IIb-IIIa acts as an additional receptor for 
fibrinogen and Von Willebrand Factor helping to form a firm haemostatic plug to the vessel wall2,3.  
 
Degranulation of platelets also releases Factor XII or Hageman factor, which combined with the platelet 
factor 3, initiates a cascade of the serial activation of factors XI (Antihaemophiliac factor C), IX 
(Antihaemophiliac factor B), and VIII (Antihaemophiliac factor A), and finally factor X (Thrombokinase), 
the intrinsic pathway of the coagulation cascade. Simultaneously the extrinsic pathway of the 
coagulation cascade is activated by the release of factor III (thromboplastin) from the damaged 
endothelium and perivascular tissues, activating factor VII (Proconvertin) and subsequently factor X3. 
 
Once factor X is activated both intrinsic and extrinsic pathways are identical. The combination of factor 
X with factor III and factor V (Proaccelerin) when platelet factor 3 and Calcium are also present results 
in the production of prothrombin activator which converts factor II (Prothrombin) into thrombin, an 
enzyme which converts the soluble plasma protein fibrinogen into insoluble fibrin2,3 which creates a 
“framework” for clot development. Again, a positive feedback cycle resulting from the coagulation 
cascade enzymes results in the continued production of clot.  
 
The following image5 illustrates the coagulation cascade including points where anticoagulant 





While in normal physiological clotting this process is followed by tissue repair, remodelling and eventual 
fibrinolysis of the clot, the clotting process can become pathological when the thrombus continues to 




Locally, pathological deep vein thrombosis (DVT) obstructs the flow of blood through the vein, resulting 
in increased venous hydrostatic pressure. This may be asymptomatic or present clinically with pain, 
heat and swelling in the affected extremity. Well’s score6  can be used to predict the relative probability 
of DVT based on history and clinical examination findings. When suspicion is high, diagnosis is able to 
be confirmed in several ways. In the modern clinical setting this is most commonly and least invasively 
done by use of ultrasound, however historically and in research settings the invasive but highly 
sensitive method of contrast venography has also been used. 
 
Well’s scoring system can be illustrated by: 
CHARACTERISTIC SCORE 
Clinical signs or symptoms of DVT 3 
PE is most likely or equally likely diagnosis 3 
Heart rate >100 1.5 
Immobility of 3 or more days OR surgery within 
the preceding 4 weeks 
1.5 
Previous objective diagnosis of PE/DVT 1.5 
Haemoptysis 1 




0 - 1 = Low risk 
2 - 6 = Moderate risk 





Thromboembolism occurs when a mass of thrombus embolises, travelling within the venous system 
until it reaches a vessel with a lumen too small to permit its passage and occludes the vessel2. DVT 
developing in the systemic veins will travel first to the heart, and then if it is of small enough size to 
pass through the heart, into the pulmonary vasculature. The size of the embolus and hence the size of 
the occluded vessel determine the significance of the resultant effects of the embolus. Large emboli 
have the potential to cause death if the obstruction occurs in the heart or large vessels.  
 
Presentation and management of VTE 
 
Clinical presentation of VTE 
 
Large pulmonary emboli which obstruct the heart or large pulmonary vessels obstruct cardiac output 
and consequently result in the sudden development of haemodynamic shock, rapidly progressing into 
cardiac arrest and death often occurring over a timeframe of only minutes from the embolic event3. 
Obstruction of moderate to larger sized pulmonary arteries but not resulting in sudden death causes a 
sudden increase in pulmonary vascular resistance and pulmonary artery pressure, with backpressure of 
blood into pulmonary artery capillaries. This results in hypoperfusion of the lung and ventilation 
perfusion (VQ) mismatch in the affected part of the lung, with resultant increase in alveolar dead space, 
hypoxia and hypercarbia, and possible pulmonary infarction.  
 
Clinically, the classical presentation of pulmonary embolus is of a patient with pleuritic chest pain, 
breathlessness and desaturation. Tachypnoea and tachycardia occur as a result of attempted 
compensatory mechanisms. There may be respiratory acidosis, however alkalosis from compensatory 
tachypnoea is also possible. Increased right ventricular pressures and right heart strain as a result of 
increased pulmonary resistance may be evident on electrocardiogram (ECG) as the combination of S 
waves in lead I, Q waves in lead II and inverted T wave in lead III, although the most common ECG 
finding in patients with pulmonary embolus is the nonspecific finding of a sinus tachycardia. 
Hypoperfusion causing decreased surfactant production by alveolar type 2 cells can also contribute to 
atelectasis and pulmonary oedema, further exacerbating VQ mismatch7. In the case of smaller 
pulmonary emboli causing occlusion of minor pulmonary vessels the patient may still present with 
pleuritic chest pain and breathlessness to a lesser degree of severity, or in some cases may be 
asymptomatic. 
 
Investigation and Confirmation of Diagnosis 
 
The preferred investigation to confirm diagnosis of PE is computed tomography pulmonary angiography 
(CTPA)8, where the clot is demonstrated by a filling defect within the pulmonary arteries which are 
opacified by contrast media. Use of CTPA may not be possible in patients whose initial presentation is 
too unstable for CT, those who have a an allergy to contrast media or in those who have significant 
renal failure making the risk of contrast induced nephropathy outweigh the benefit of the investigation. 
An alternative for patients who are not suitable to undergo CTPA is the Nuclear Medicine investigation 
of ventilation perfusion scintigraphy (VQ scan)9,10 which utilises an inhaled radiopharmaceutical to 
detect areas of the lung which are ventilated but not perfused. Examples illustrating the images 









Image 4a: V/Q scan image demonstrating normal VQ scan 9 
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Treatment options once a Pulmonary embolus has occurred include initial resuscitation (including with 
Cardiopulmonary resuscitation (CPR) if the patient is in extremis), supplemental oxygen and fluids, 
followed by anticoagulation and potential thrombolysis. Rarely, in the event of large emboli and a 
surviving patient, a thrombectomy may be performed. In more stable patients with smaller pulmonary 
emboli, treatment consists of anticoagulation and supportive care, in addition to treatment of any 
identified precipitating conditions. Therapeutic dose anticoagulation is usually continued for several 
months after the embolic event, and in some cases may be lifelong. 
 
Risk Factors for VTE 
 
Multiple factors can increase an individual’s risk of VTE from baseline, usually by their effect on one of 
the components or Virchow’s triad described above.  
Of particular relevance to patients undergoing major open abdominal or pelvic surgery for malignancy, 
open approach11 and malignancy12 itself both independently carry increased risk of thrombosis 
formation.  
 
Patient Position, Surgery and Venous Flow 
 
Regarding operative factors, any abdominal or pelvic surgery is a significant trauma resulting in a 
systemic inflammatory response, with consequent release of inflammatory factors and increased 
coagulability of the blood. The surgical trauma itself includes a degree of direct endothelial damage to 
vessels intentionally or inadvertently ligated, removed or temporarily clamped as part of the procedure, 
as well as those affected by the placement of arterial or central venous lines for the purposes of close 
intraoperative monitoring. Anaesthesia and immobility during the procedure also causes in venous 
stasis. Stasis can be further exacerbated by specific patient positioning frequently employed 
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intraoperatively to aid exposure and access to the pathology being targeted. Common intraoperative 
positioning used in open abdominal and pelvic procedures include head down and lithotomy positions. 
These positions can further increase risk of VTE via reducing venous flow for example hip flexion 
during prolonged lithotomy compressing and kinking large pelvic veins.  
 
While the use of insufflation and resultant temporary increase in abdominal pressures during 
laparoscopic or robotic procedures may also contribute to an increased risk DVT and VTE, in the 
majority of cases an open approach to the procedure results in both greater tissue trauma and higher 
postoperative pain levels13. Increased postoperative pain contributes to comparatively longer inpatient 
hospital stay and rehabilitation periods where there is ongoing reduced venous blood flow secondary to 
reduced mobility as compared to the patient’s baseline activity. Finally, a patient’s selection for an open 
approach to an abdominal or pelvic procedure may in many cases be related to a more advanced 
disease process or particularly complex prior surgical history that makes a minimally invasive approach 
unlikely to be feasible. Therefore the same characteristics that select a patient for an open approach, 
are also potentially associated with that patient having a more technically challenging and or longer 
duration procedure, which further increases VTE risk by longer intraoperative time of immobility, 
intraoperative temperature fluctuations and possible blood loss and transfusion requirement over the 
intraoperative course. In the postoperative period, patients with advanced disease who have undergone 
long, complex open procedures are at higher risk of other postoperative complications such as pelvic 
haematoma or seroma, which themselves are independently associated with an increased risk of DVT 
and VTE, for example by haematoma or seroma causing extrinsic compression of major pelvic veins 
leading to reduced venous return and stasis.  
 
Thus, even if other patient factors are not considered, undergoing an open abdominal or pelvic surgical 
procedure alone significantly increases any patient’s risk of VTE, with all components of Virchow’s triad 
impacted. 
 
Hypercoagulable State in malignancy 
 
Solid or visceral malignancy of any type causes a pro-coagulable state. While the exact mechanism of 
this is complex and not yet fully understood, current factors thought to play a significant role include 
direct production of procoagulant, fibrinolytic and pro-aggregant agents by tumour cells, release of 
proinflammatory and proangiogenic cytokines, direct interactions via adhesion molecules between 
tumour cells and host vascular and blood cells and altered platelet, leucocyte and Tissue Factor (TF) 
counts in malignancy patients14.  
 
Patients with malignancy undergoing open abdominal or pelvic surgery may also have other non-
modifiable risk factors for VTE including advanced age, limited baseline mobility, previous VTE or 
hereditary pro-thrombotic disorders such as factor V Leiden deficiency or Protein C&S deficiency. 
Modifiable risk factors include obesity, tobacco smoking and use of postmenopausal hormone 
replacement therapy or the oral contraceptive pill15. However, given the need for surgical treatment of 
malignancy to be performed in a timely fashion following diagnosis before further progression of 
disease, there may be only limited opportunity to significantly alter these factors. For example regarding 
obesity, the length of time required to achieve sufficient weight loss as to be beneficial would mean it is 
exceptionally unlikely any reduction of VTE risk by weight loss would not be outweighed by harm to the 




The risk of VTE can be mitigated to some extent by providing prophylaxis (preventative treatment). VTE 





Mechanical prophylaxis includes the use of graduated compression stockings (GCS), pneumatic 
compression devices and early postoperative mobility. Mechanical prophylaxis should be provided to all 
patients and include all measures unless there are specific contraindications to their use in that patient. 
 
Graduated compression stockings exert graded compression on the limb, with the greatest 
compression provided at the ankle and progressive reduction in compressive force moving proximally. 
This theoretically results in increased venous pressure and therefore increased antegrade flow of blood 
with reduced venous reflux and stasis, as well as increased lymphatic drainage of the limb16. A previous 
Cochrane Review concluded that there is high quality evidence that GCS provide an effective reduction 
in risk of VTE in both general and orthopaedic surgery17. Contraindications to use of GCS are few, but 
include severe peripheral arterial disease or bypass grafting, severe peripheral neuropathy or other 
sensory impairment, and local skin or soft tissue conditions such as chronic ulcers, broken or extremely 
fragile skin, cellulitis, or conditions that prevent appropriate fitting of the stocking such as extreme 
deformity, massive peripheral oedema and or pulmonary oedema from congestive cardiac failure16. 
Care must be taken to ensure the stockings are worn correctly and there is no wrinkling of the stocking 
material causing localised constriction of the limb and risking pressure injuries. 
 
Intermittent pneumatic compression devices (IPCDs) consist of inflatable sleeves fitted to the limb with 
a connected air pump that intermittently inflates the sleeve. Their mechanism of action is by external 
compression of the limb indirectly causing compression of the veins and so simulating the skeletal 
muscle pump of the calf muscles in mobilisation, increasing venous blood flow and reducing stasis18. 
Contraindications to their use include known pre-existing DVT or PE (as it is thought the force of the 
intermittent compressions may increase the risk of a DVT embolising), thrombophlebitis and local skin 
disease such as ulcers, wounds or cellulitis. A proportion of patients have been reported not to tolerate 
use of IPCDs due to finding the compression uncomfortable, or the noise of the air pump irritating. 
 
Early postoperative mobilisation should be encouraged with the aim of the patient returning to their 
baseline preoperative mobility as quickly as possible postoperatively. This is arguably the most 
important component of mechanical VTE prophylaxis and is ideally approached with a multidisciplinary 
team. The multidisciplinary team includes the treating surgical team, ward nursing staff, and utilisation 
of specialised input from physiotherapists to assess and assist patients with safe mobility, and at times 
occupational therapists or prosthetists where mobility aids are required. Consultation with anaesthetic 
and pain physicians is also crucial in order to optimise analgesia and ensure postoperative pain is 
sufficiently controlled as to not unduly impair the patient’s ability to participate in mobilisation.  
 
Finally, optimising compliance with mechanical prophylaxis also requires commitment to effective 
patient education so the patient has awareness of VTE and its significance, and thus the importance of 
and reasons for each prophylactic strategy. Clear and consistent information including written 





Pharmacological prophylaxis refers to the use of medication to reduce the blood’s ability to clot via their 
effect on particular steps of the coagulation cascade described above. Commonly used anticoagulants 




While all have been documented to have been used in VTE prophylaxis and therapeutic 
anticoagulation, heparins are the most commonly used agent in Australia, and are the recommended 
prophylactic agent in best practice guidelines including the current BJUI19 recommendation, those 
previously produced by the American Urological Association1, and the American College of Chest 
Physicians20. These guidelines specifically recommend low molecular weight (LMWH) or unfractionated 
heparin in patients who are at high risk of VTE. Consequently, for the purposes of this study we chose 
to focus on the use of heparin, in particular Enoxaparin (a low molecular weight heparin) in VTE 
prophylaxis. 
 
Action of Heparin: 
 
Heparins are acidic mucopolysaccharides that inhibit coagulation by potentiating the development of 
complexes between antithrombin and activated serine protease coagulation factors and factors IIa IXa, 
Xa and XIa, irreversibly inactivating these factors and thus preventing the conversion of prothrombin to 
thrombin and fibrinogen to fibrin. Unfractionated heparin also inhibits platelet function21.  
 
Enoxaparin is a low molecular weight heparin (as opposed to unfractionated) heparin, produced by 
depolymerisation of unfractionated heparin. Compared to unfractionated heparin it has a greater ability 
to inhibit factor Xa and reduced interaction with platelets as well as a greater bioavailability and a longer 
plasma half-life. These characteristics mean enoxaparin is considered an ideal agent for VTE 
prophylaxis as its half-life of approximately four hours after subcutaneous administration enables once 
daily administration. In addition there is a lower frequency of complications such as heparin induced 
thrombocytopaenia with Enoxaparin. In addition, an antidote, protamine, is available should its 
anticoagulant effect need to be reversed23. Specific individual factors that must be taken into 
consideration for enoxaparin use and dose adjustment include patient weight and renal function as it is 
renally excreted22. 
 
Consideration in use of Heparins: 
 
However, as with all interventions, the benefit of prophylaxis must be weighed against the potential for 
adverse events. Known complications of pharmacological VTE prophylaxis include both major and 
minor haemorrhage, heparin induced thrombocytopaenia, elevation of serum aminotransferases, 
infection associated with haematoma at administration sites, hypersensitivity and local reactions22. With 
increased duration of prophylaxis there will be an increase in prophylaxis related adverse events, up to 
a point where this may outweigh the benefit of the prophylaxis. At what duration of prophylaxis this 
point is reached remains unclear. However, with the exception of major haemorrhage, infection and 
anaphylaxis, these complications likely pose a relatively smaller threat to patients than that associated 
with clinically detectable VTE. Furthermore, a patient diagnosed with VTE would be expected to be 
treated with more aggressive therapeutic dose anticoagulation than that given for prophylaxis for a 
longer treatment duration, thus exposing them to a higher risk of these complications than is associated 
with prophylaxis. Other minor disadvantages to its use include the need for parenteral administration as 
it is not absorbed from the gastrointestinal tract, which results in the risk of local administration site 
complications.  
 
Duration of prophylaxis and relation to aims of project 
 
Despite the consensus that risk of VTE extends for a significant period of time postoperatively, to date 
literature reviews have found insufficient evidence to determine an exact timeframe for this risk and 
consequently have not been able to make an evidence-based recommendation for optimum duration of 
postoperative prophylaxis19.  
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In addition, there does not appear to be a consistent pattern of use of postoperative pharmacological 
VTE prophylaxis in abdomino-pelvic oncological surgery patients. This is possibly largely due to the 
generalised nature of current recommendations. Despite this, extended duration use appears to be 
becoming increasingly common. This may be explained by the fact that benefits of extended duration 
prophylaxis have been well documented in other specialties20 and many practitioners therefore believe 
these could reasonably be expected also to apply to open abdomino-pelvic oncological surgery 
patients. However, it is questionable whether it is appropriate to apply evidence generated in other 
specialties to this population, as despite the observed similarities, equally there are a number of 
differences and so whether the populations are truly equivalent in relation to benefit and risks of 
prophylaxis is unknown.  
 
Consequently, further investigation is warranted to define the optimum duration of postoperative 
pharmacological VTE prophylaxis with heparin following major abdomino-pelvic oncological surgery, 
with the goal being to determine the most effective reduction in population risk of VTE without 
disproportionately increasing the risk of heparin associated adverse events or cost of treatment.  
Identifying this and thus enabling an evidence-based recommendation to be made regarding 
recommended duration would enable all abdominal and pelvic oncological surgery patients to receive 
standardised best practice postoperative pharmacological VTE prophylaxis. 
 
The primary aim of this work was therefore to contribute to potentially developing such an evidence 
based recommendation, by performing a systematic literature review and meta-analysis of existing 
literature, looking specifically at patients undergoing major open abdominal or pelvic surgery for 
malignancy and  comparing the effectiveness and safety of postoperative inpatient versus extended 
venous thromboembolism (VTE) prophylaxis with heparin in this population. Subsequently a secondary 
aim is to use the findings of this literature review to evaluate the economic implications of this treatment 
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Venous Thromboembolism (VTE) is a common postoperative complication associated with significant 
morbidity and mortality. Use of prophylactic heparin postoperatively reduces this risk, and use of 
extended duration prophylaxis is becoming increasingly common. Malignancy and pelvic surgery both 
independently further increase the risk of postoperative VTE, and patients undergoing major pelvic 
surgery for malignancy are at particularly high risk of VTE. However, optimum duration of prophylaxis 
specifically in this population currently remains unclear. 
 
METHODS 
We will conduct a systematic review of literature in accordance with the Cochrane Handbook for 
Systematic Reviews of Interventions23 to evaluate current evidence of the effectiveness and safety of 
inpatient versus extended VTE prophylaxis with Heparin (all forms) following major pelvic surgery for 
malignancy. We will search PubMed, EMBASE, and the Cochrane Library. Regarding safety, Food and 
Drug Administration (FDA) and Therapeutic Goods Administration (TGA) websites will be searched, 
including all levels of evidence. Results will be the postoperative timeframe in which a VTE event can 
be considered to have been provoked by the surgery, and the number of patients needed to treat with 
both inpatient and extended prophylaxis to prevent a VTE event in this timeframe, comparing these to 
determine if there is a significant benefit from extended prophylaxis. 
 
DISCUSSION 
This systematic review will aim to identify the postoperative period in which patients undergoing major 
pelvic surgery for malignancy are at further increased risk of VTE as a result of their surgery, and the 
optimum duration of VTE prophylaxis with heparin to reduce this risk. Determining this will allow 
evidence-based recommendations to be made for optimum duration of heparin VTE prophylaxis post 
major pelvic surgery for malignancy, leading to improved standards of care that are consistent between 
different providers and institutions. 
 
SYSTEMATIC REVIEW REGISTRATION: 
In accordance with guidelines, our systematic review was submitted to PROSPERO for consideration of 
registration on 16/12/17 and was registered on 12/1/18 with the registration number CRD42018068961, 
it was last updated on 12/1/18. 
 
KEYWORDS 






Venous thromboembolism (VTE) is a common postoperative complication associated with significant 
morbidity and mortality1. A major risk factor for VTE is type of surgery, with patients undergoing major 
oncological surgery or pelvic surgery being at significant risk1. These patients frequently also have 
additional non-modifiable risk factors for VTE including advanced age, limited mobility, previous VTE or 
hereditary pro-thrombotic disorders. However, these risks can be mitigated by providing mechanical 
and or pharmacological prophylaxis. Best practice guidelines including the current BJUI19 
recommendation and those previously produced by American Urological Association1, recommend the 
use of low molecular weight (enoxaparin) or unfractionated heparin in patients who are at high risk of 
VTE.  
 
However, despite consensus that the risk of VTE extends for a significant period postoperatively, to 
date literature reviews have found insufficient evidence to determine an exact timeframe for this, and 
consequently have not been able make an evidence-based recommendation for the optimum duration 
of prophylaxis19. In addition, there does not appear to be a consistent pattern of use of postoperative 
pharmacological VTE prophylaxis in pelvic oncological surgery patients. 
 
As with all interventions, the benefit must be weighed against the potential for adverse events. Known 
complications of pharmacological DVT/VTE prophylaxis include both major and minor haemorrhage, 
thrombocytopaenia, elevation of serum aminotransferases, infection associated with haematoma, 
hypersensitivity reactions and local reactions22. With increased duration of prophylaxis there will be an 
increase in prophylaxis related adverse events, up to a point where these outweigh any ongoing benefit 
of the prophylaxis – again, at what duration of prophylaxis this point is reached remains unclear.   
 
Consequently, further investigation is warranted and we aim to define the optimum duration of 
postoperative pharmacological VTE prophylaxis with heparin following major pelvic oncological surgery 
to provide the most effective reduction in population risk of VTE without disproportionately increasing 
the risk of heparin associated complications. Identifying this and making an evidence-based 
recommendation would enable all pelvic oncological surgery patients to receive standardised best 





The aim of this systematic review is to review the currently available literature to evaluate the 
effectiveness and safety of inpatient versus extended VTE prophylaxis with Heparin (all forms) following 
major pelvic surgery for malignancy answering the following questions: 
1. Timeframe postoperatively in which a VTE event can reasonably be considered to have been 
provoked by the surgical procedure 
2. Number needed to treat (NNT) with inpatient prophylaxis to prevent one VTE event within the 
timeframe established by 1. 
3. NNT with extended prophylaxis to prevent one VTE event within the timeframe established by 
1 
4. Considering the results of 2 and 3, is there a significant benefit associated with extended 
prophylaxis in reducing risk of VTE events?  
5. Considering result of 4, if extended prophylaxis is shown to significantly reduce VTE events in 
the postoperative period established in 1, does this benefit outweigh the associated risks of 
extended prophylaxis – ie is extended prophylaxis safe? 
 
DESIGN - SEARCH STRATEGY & INFORMATION SOURCES 
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Literature search regarding both effectiveness and safety will be conducted by searching PubMed, 
EMBASE (2008-present), and Cochrane databases from inception to present. Regarding safety, Food 
and Drug Administration (FDA) and Therapeutic Goods Administration (TGA) websites will be reviewed 
in addition to targeted searches of Health Technology Assessment databases such as ‘EuroSCAN’ 24 to 
identify any further grey literature reporting of adverse events that may have been reported to these 
bodies but not published within a research paper and therefore not captured by the database search. 
In addition to the electronic database and regulatory website search described above we will review 
public registries of clinical trials and the reference lists of included literature and the published work of 
authors listed, with the aid of tools such as SCOPUS. 
 
Search terms will include the medical subject headings (MeSH) and keywords combined by Boolean 
operators: Venous Thromboembolism OR VTE OR Deep vein thrombosis OR DVT AND Pelvic OR 
Malignancy OR Oncology AND Heparin OR Enoxaparin AND Prophylaxis. Refer to appendix 1 for 
search strategy. 
 
DESIGN -  ELIGIBILITY CRITERIA 
1. We will include English language studies of NHMRC level of evidence I-V. The decision to 
include case reports (level V) and case series was made as it was felt these would be 
useful to identify adverse events.  
2. Participants; participants will be the subjects of all included literature, including adult (18 
years and older) patients of either gender undergoing pelvic surgery for malignancy 
3. The intervention will be the use of extended pharmacological VTE prophylaxis (as opposed 
to in hospital pharmacological prophylaxis) with any form of heparin postoperatively, with 
the assumption made that all patients receiving pharmacological prophylaxis also received 
non-pharmacological VTE prophylaxis (eg compression stockings, sequential compression 
devices) 
4. The comparator will be inpatient versus extended use of heparin VTE prophylaxis 
5. Outcomes; endpoints considered will include 
a. VTE events 
b. Heparin associated complications; classified by Clavien-Dindo grade25. 
6. Studies published within the last ten years up to and included the date the literature search 
was completed will be included. The decision to exclude studies published more than ten 
years ago was made to ensure that included literature more closely reflects recent clinical 
practice and is therefore relatively representative of the current day patient population and 
care. 
7. Setting will be inpatient and community patients receiving pharmacological VTE 
prophylaxis with heparin postoperatively 
 
DESIGN - SELECTION PROCESS  
Retrieved articles will be independently reviewed by primary author and peer reviewer and included or 
excluded by the pre-determined criteria described above. 
 Articles will first be shortlisted for inclusion or discarded based on their title. Of those shortlisted by title, 
the abstract will be reviewed and the papers returned to the shortlist or discarded by the relevance of 
the abstract. Those included or unclear based on the abstract will proceed to review of the entire article 
by both the primary and second author, who will independently document if they would include or 
discard the article. 
Should there be a disagreement between the primary and secondary reviewer, the article will be 
additionally reviewed by the supervisors of the project and a reasonable effort made to contact the 
author for any clarification required on the included material.  
Exclusion criteria will include non-English language papers as the team lacks the resources available to 
translate these, paediatric populations and animal studies. Non-English language papers with an 
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English abstract will be listed as potentially relevant studies awaiting assessment in the review to alert 
the reader of these papers’ existence in a wider evidence base. 
 
DESIGN - DATA COLLECTION PROCESS 
A template form of data variables to be extracted will be produced, and reviewers will independently 
complete this for each article reviewed, and additionally transcribe the data points into separate excel 
spreadsheets. Each reviewer’s assessment will then be compared and in the event of any 
discrepancies not able to be resolved on re-review the article will be reviewed by a supervisor, following 
which if the discrepancies remain unresolved reasonable attempts will be made to seek clarification 
from the author.  
A template of this in table form is included as an Appendix to this document. 
 
DESIGN - DATA ITEMS  
Variables to source data for 
- Timing of starting heparin postoperatively 
- Total duration heparin prophylaxis; inpatient versus extended. This will be considered a 
dichotomous variable, with patients categorised into those receiving prophylaxis whilst a 
hospital inpatient or those receiving ongoing prophylaxis of any duration on discharge.  
- VTE events 
- Event that may be considered complications of prophylaxis and determine their Clavien Dindo 
grade25 
- Type of surgery (primary or revision). If sufficient data is identified this may subsequently be 
used to conduct further analysis comparing outcomes of primary and revision procedures. 
- Disease histology. If sufficient data is identified this may subsequently be used to conduct 
further analysis by each oncologic pathology. 
Assumptions made  
- Inpatient stay will be considered a single duration despite the fact that inpatient stay 
postoperatively may be of variable length as this remains of significant impact due to altered 
mobility/activity from baseline while in inpatient setting 
- Concurrent use of mechanical prophylaxis; it will be assumed all patients received mechanical 
VTE prophylaxis in addition to pharmacological as the instances in which this is contraindicated 
are uncommon 
- Assume all patients receive an appropriate dose of pharmacological prophylaxis for their 
individual condition (ie appropriate for body habitus, appropriate reduction in dose for impaired 
renal function). However, if it is possible from the included data to confirm an appropriate dose 
was used this will be confirmed. 
- Potential VTE events not diagnosed on Ultrasound (US)/Computed tomography pulmonary 
angiography (CTPA)/V/Q Scan are of sufficiently insignificant impact on the individual’s 
recovery as to be irrelevant to the outcomes of the study. 
 
DESIGN - OUTCOMES PRIORITISATION 
The primary outcome will be the number of clinically evident VTE events in patients treated with 
prophylactic heparin following major pelvic surgery for malignancy, subdivided into those treated only 
whilst inpatient immediately postoperatively and those treated with an extended course. Clinically 
evident VTE will be defined as that confirmed on investigation with US/CTPA. Any incidence of VTE not 
detected by these means will be interpreted as being sufficiently minor as to be clinically insignificant. In 
addition, any diagnoses of VTE made purely on the basis of history and examination findings without 
objective evidence of confirmed VTE on these modalities will be excluded as the clinical presentation of 
VTE is nonspecific and thus this may not represent a true VTE event. 
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Secondary outcomes will include both adverse events attributable to use of pharmacological VTE 
prophylaxis such as bleeding/haematoma/thrombocytopaenia/drug reaction, and in association with 
identified VTE events; length of stay/ICU admission/readmission to hospital following discharge. 
 
DESIGN - RISK OF BIAS AND PLANNED ASSESSMENT OF META BIAS 
Potential sources of bias in this review will be from pre-existing bias in reviewed articles, publication 
bias and potential of data censuring. Risk will be minimised by use of appropriate critical appraisal tools 
(e.g. AMSTAR2 for Systematic reviews26 and Cochrane tool27 for randomised controlled trials) to 
critically assess each article and consider exclusion of low scoring articles. 
 
DESIGN - DATA SYNTHESIS 
Statistical advice regarding the most appropriate method of analysis will be sought following literature 
search prior to data extraction. Should identified articles be of sufficient number and quality, data may 
be further broken down by cancer type.  
 
DESIGN - HOW THE STRENGTH OF THE BODY OF EVIDENCE WILL BE ASSESSED 
The strength of the body of evidence will be assessed using the GRADEpro tool28.  
 
DESIGN - STUDY RECORDS 
Record of the details (Title, Author(s), Where published, Date of publication, Access date, Reasoning 
behind decision to include) of all included articles will be kept in an excel spreadsheet. Those relevant 
to effectiveness will be kept on a separate page of the spreadsheet to those relevant to safety, and 
those relevant to both effectiveness and safety duplicated across both pages. 
The second author will keep an additional database of the articles they have reviewed and their 
reasoning for their recommendation that the article be included or discarded.  
Details of articles initially identified on scoping search and subsequently excluded will be kept in a 
separate excel document which will also lists the reason for their exclusion. 
 
DESIGN – PROCESS OF DEALING WITH AMENDMENTS TO PROTOCOL 
A copy of the protocol will be saved and kept both without and with amendments, giving a new version 
number to the amended copy; thus versions at all stages of amendments remain available. Other 
contributors will be notified of amendment via email 
 
DISCUSSION  
As this protocol is for a systematic review of pre-existing literature, minimal operational issues are 
anticipated, with the primary difficulty anticipated being any situation where the full text of an identified 
article is not accessible. This will be managed on a case by case basis with the available text (e.g. 
abstract) of the article reviewed by both reviewers and the project supervisors to determine if it is 
suitable for inclusion or not. Should a consensus not be able to be reached the article will be included. 
We acknowledge limitations of this review including potential sources of bias described in methods and 
including only English language publications. 
 
LIST OF ABBREVIATIONS 
AUA: American Urological Association 
BJUI: British Journal of Urology International 
DVT: Deep Vein Thrombosis 
MeSH: Medical Subject Headings 
NNT: Number needed to treat 
TGA: Therapeutic Goods Administration 
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ADDITIONAL FILE 1. SEARCH STRATEGY 
 
(((((((((aspirin) OR dalteparin) OR warfarin) OR low molecular weight heparin) OR enoxaparin) OR 
heparin)) OR ((((((heparin, low molecular weight[MeSH Terms]) OR aspirin[MeSH Terms]) OR 
warfarin[MeSH Terms]) OR dalteparin[MeSH Terms]) OR enoxaparin[MeSH Terms]))) AND 
(((((((((((((((((((cancer, uterine cervical[MeSH Terms] OR cervical cancer) OR urethral cancer[MeSH 
Terms]) OR urethral cancer) OR cancer, prostate[MeSH Terms]) OR prostate cancer) OR cancer, 
uterine[MeSH Terms]) OR uterine cancer) OR cancer, ovarian[MeSH Terms] OR ovarian cancer) OR 
colorectal cancer[MeSH Terms]) OR bowel cancer) OR cancer of the ureter[MeSH Terms]) OR ureteric 
cancer) OR bladder cancer) OR bladder cancer[MeSH Terms])) OR ((((“Abdominal Neoplasm”[Mesh]) 
OR abdominal neoplasm)) OR ((pelvic neoplasms) OR “Pelvic Neoplasms” [Mesh]))) 
 
 
ADDITIONAL FILE 2: DATA COLLECTION TEMPLATE 
 
Article 1 2 3 
Title    
Author(s)    
Year of Publication    
Journal    
NHMRC Evidence Level     
Malignancy diagnosis/ese    
Procedure(s)    
Major intervention  
(Including dose/route/frequency/duration) 
- Number post exclusions 
   
Comparator 
(Including dose/route/frequency/duration) 
- Number post exclusion 
   
Outcomes 
- How were these defined 
- How were these measured 
   
Conclusions    
EFFICACY OUTCOMES 
Mortality rate secondary VTE    




   







   
Number of transfusions    
Wound complications    
Other adverse events    
Readmissions    
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BACKGROUND: Patients undergoing open abdomino-pelvic procedures for malignancy are at high risk 
of postoperative venous thromboembolism (VTE). This risk can be mitigated with prophylaxis, however 
optimum duration in this population remains unknown. Our objective was to conduct a systematic 
review of contemporary literature on use of heparin thromboprophylaxis following major open pelvic 
surgery for malignancy, comparing the efficacy and safety of extended duration to inpatient treatment. 
 
METHODS: A study protocol describing search strategy, inclusion and exclusion criteria was developed 
and registered with PROSPERO. A literature review was conducted in accordance with the protocol. 
 
RESULTS: Literature review identified only four studies directly comparing extended and inpatient 
duration prophylaxis, with a combined population of 3198 and 3135 patients for VTE rate and bleeding 
events respectively. Despite many studies reporting lower VTE rates in patients receiving extended 
prophylaxis, no statistically significant difference in rates of postoperative VTE (p=0.18) or bleeding 
complications (p=0.43) was identified between patients receiving extended duration prophylaxis and 
those receiving inpatient only prophylaxis.  
 
CONCLUSION: On review of contemporary literature, no significant difference was found in rates of 
postoperative VTE or bleeding complications between patients receiving extended duration heparin 
VTE prophylaxis and those receiving inpatient prophylaxis after open abdominopelvic surgery for 
malignancy. 
This raises the question of how extended duration prophylaxis has become common practice in this 














Venous thromboembolism (VTE) is a common postoperative complication associated with significant 
morbidity and mortality1. A major risk factor for VTE is type of surgery, with patients undergoing major 
oncological surgery or pelvic surgery being at significant risk19. These patients frequently also have 
additional non-modifiable risk factors for VTE including advanced age, limited mobility, previous VTE or 
hereditary pro-thrombotic disorders. However, these risks can be mitigated by using prophylaxis. Best 
practice guidelines including the current British Journal of Urology (BJUI)19recommendation and those 
previously produced by American Urological Association (AUA)1, recommend the use of low molecular 
weight heparin (enoxaparin) or unfractionated heparin in patients who are at high risk of VTE although 
they do not specify an exact quantified recommended duration of treatment.  
 
However, despite consensus that the risk of VTE extends for a significant period postoperatively, to 
date literature reviews have found insufficient evidence to determine an exact timeframe for this, and 
consequently have not been able make an evidence-based recommendation for the optimum duration 
of prophylaxis19. In addition, there does not appear to be a consistent pattern of use of postoperative 
pharmacological VTE prophylaxis in pelvic oncological surgery patients. 
 
As with all interventions, the benefit must be weighed against the potential for adverse events. Known 
complications of pharmacological DVT/VTE prophylaxis include both major and minor haemorrhage, 
thrombocytopenia, elevation of serum aminotransferases, infection associated with hematoma, 
hypersensitivity reactions and local reactions22. With increased duration of prophylaxis there will be an 
increase in prophylaxis related adverse events, up to a point where these outweigh any ongoing benefit 
of the prophylaxis – again, at what duration of prophylaxis this point is reached remains unclear. 
Furthermore, extending the duration of VTE prophylaxis beyond what is required adds an economic 
burden to the health care system.  
 
Consequently, further investigation is warranted to define the optimum duration of postoperative 
pharmacological VTE prophylaxis with heparin following major pelvic oncological surgery to reduce the 
risk of VTE without disproportionately increasing the risk of heparin associated complications. 
Identifying this and making an evidence-based recommendation would enable all pelvic oncological 
surgery patients to receive standardized best practice postoperative pharmacological VTE prophylaxis. 
 
In this article we conduct a meta-analysis of inpatient versus extended duration VTE prophylaxis in 
patients undergoing pelvic surgery for malignancy.  Extended use was defined as any continuation of 
pharmacological VTE prophylaxis after discharge from the index hospital admission, with inpatient use 
defined as the use of pharmacological VTE prophylaxis for the majority of the index hospital inpatient 
admission. 
 
METHODS: A study protocol describing search strategy, inclusion and exclusion criteria was developed 
and registered with PROSPERO (CRD42018068961).  
 
In accordance with the protocol, literature search was conducted of PubMed, EMBASE, and Cochrane 
databases. Search terms included medical subject headings (MeSH) terms and keywords combined by 
Boolean operators: aspirin, dalteparin, enoxaparin, warfarin, heparin, low molecular weight heparin, 
abdominal neoplasm, pelvic neoplasm, prostate cancer, bladder cancer, ureteric cancer, urethral 
cancer, ovarian cancer, cervical cancer, uterine cancer. 
 
Search results were screened by the primary author and initially shortlisted for inclusion or discarded 
based on the relevance of the title to the protocol. Of those shortlisted by title, the abstract was 
reviewed and the papers returned to the shortlist or discarded based on the relevance of the abstract. 
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Those included or unclear based on the abstract proceeded to review of the entire article by both the 
primary author and second peer reviewer, who independently documented if they would include or 
discard the article. Disagreement was resolved by discussion between the reviewers.  
 
Studies identified were eligible for inclusion in the review if they met inclusion criteria of being English 
language studies of adult patients published within the last ten years at the time of literature search. All 
National Health and Medical Research Council (NHMRC) levels of evidence (I-V) were included as it 
was felt the inclusion of case series and case reports remained important as a means of capturing 
reporting of adverse events. Non-English language papers, paediatric populations, non-operative or 
exclusively laparoscopic surgical populations and animal studies were excluded.  While other 
antithrombotic agents (warfarin, aspirin) were included in the initial search terms with the aim of 
capturing a broad range of literature on postoperative thromboprophylaxis, a decision was made to 
assess only papers regarding heparin thromboprophylaxis and those utilising other forms of 
thromboprophylaxis were excluded. 
 
The intervention of interest was the use of extended pharmacological VTE prophylaxis with any form of 
heparin postoperatively following major open abdominal or pelvic surgery for malignancy, with the 
comparator being inpatient use of heparin pharmacological VTE prophylaxis in this population. 
Extended use was defined as any continuation of pharmacological VTE prophylaxis after discharge 
from the index hospital admission, with inpatient use defined as the use of pharmacological VTE 
prophylaxis for the majority of the index hospital inpatient admission. The primary outcome was the 
number of clinically evident VTE events objectively confirmed on investigation with ultrasound (US), 
computed tomography pulmonary angiography (CTPA) or nuclear ventilation/perfusion (V/Q) scan in 
patients treated with prophylactic heparin following major pelvic surgery for malignancy. Secondary 
outcomes included adverse events attributable to use of pharmacological VTE prophylaxis such as 
bleeding, haematoma, thrombocytopaenia, drug reaction, and in association with identified VTE events; 
length of stay, ICU admission or readmission to hospital following discharge. 
 
Assumptions made included that all patients received an appropriate dose of pharmacological 
prophylaxis for their body habitus and pre-existing conditions such as renal impairment, and that 
patients receiving pharmacological prophylaxis also received appropriate non pharmacological VTE 
prophylaxis (such as compression stockings, sequential compression devices), and that potential VTE 
events not diagnosed on US, CTPA or V/Q scan are of sufficiently insignificant impact on the 
individual’s recovery as to be irrelevant to the outcomes of the study. Finally, despite the inherently 
variable length of individual patients’ inpatient admission, inpatient use of prophylaxis was considered 
as a single duration as the inpatient hospital setting was considered to have a significant impact on 
patient’s VTE risk due to altered mobility from baseline. Likewise, while individual extended prophylaxis 
regimes varied in their exact duration, these were considered as a single group. 
 
Following final identification of included articles and data extraction, ‘Revman’29 software was used to 
directly compare appropriate articles and produce Forest plots of these comparisons. Narrative review 
of remaining articles not appropriate for direct comparison was then performed. 
 
RESULTS: Final database search using all fields OR Mesh terms for; aspirin, dalteparin, enoxaparin, 
warfarin, heparin, low molecular weight heparin AND All fields OR Mesh terms for; abdominal 
neoplasm, pelvic neoplasm, prostate cancer, bladder cancer, ureteric cancer, urethral cancer, ovarian 
cancer, cervical cancer, uterine cancer identified 3381 articles. 
 
Of these 3381 articles, 1825 were excluded by age of publication, with a further 977 excluded on review 
of title and 540 excluded on review of abstract, leaving a total of 38 articles for full text review.  The 





Figure 1: Flow diagram summarising exclusions on literature search. 
 
Following full text review by both reviewers, a total of 18 articles met inclusion criteria. Of the 20 
excluded on full text review, reasons for exclusion included narrative reviews (four), significant 
differences in population (eight) or outcome (three), as well as two articles which simply summarized 
pre-existing guidelines, two case reports not relevant to complications of anticoagulation and one article 
that was based on a simulation only.  
 
Two pre-existing systematic reviews were identified – Fagaranasu et al30 and Akl et al31. The 
characteristics of these can be summarized in Figure 2. 
 
Figure 2: Summary of characteristics of two pre-existing reviews 
 
  Fagaranasu et al. (SR1)  Akl et al. (SR2) 
Title Role of Extended Thromboprophylaxis after 
Abdominal and Pelvic Surgery in Cancer 
Patients: A Systematic Review and Meta-
analysis 
Extended perioperative 
thromboprophylaxis in patients with 
cancer, A systematic review 
Journal Ann Surg Oncol Cellular Proteolysis and Oncology 
Year 2016 2008 
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Country Canada United States of America 
Funding Did not comment ‘Institutional support’ + one author 
funded by a European Commission 
Time period 
included 
Inception of database – May 2015 Did not comment 
Databases 
searched 




- Cochrane Register of Controlled 
Trials (Jan 2007) 
- MEDLINE 
- EMBASE 




- Abdominal surgery 
- Pelvic surgery 




- Abstracts from haematology oncology 
conferences 
- Clinical trial registries 
- Manual search of reference lists 
- Screening health technology assessments 
- Hand searching of Conference 
proceedings 
- Review of reference lists 
- Related article feature in PubMed 
Population - Adult (>18 years) patients receiving 
thromboprophylaxis with Low Molecular. 
Weight Heparin after abdominal or pelvic 
cancer surgery 
Adult patients with abdominal 




- Randomized clinical trial OR prospective 
observational cohort comparing extended 
thromboprophylaxis (2-6/52 postop) with 
conventional thromboprophylaxis (<2/52 
postop) 
- Use of thromboprophylaxis with Low 
Molecular Weight Heparin 
- All VTE outcomes objectively diagnosed 
using US/CTPA/VQ scan  
- Included asymptomatic objectively 
diagnosed VTE 
- Study reported at least one of DVT, PE, 
mortality, major bleeding 
- Adult (>18) patients  
- Randomized controlled trials 
assessing all-cause mortality, 
symptomatic DVT, Pulmonary 
Embolism, Major bleeding, Minor 
bleeding, Injection site hematoma 
and Heparin induced 
thrombocytopenia 
- Follow up rate equal to or greater 










2763 papers identified 
32 full text review 
7 eligible included studies (3 Randomized 
Controlled Trials 4 observational) 
3986 papers identified 
3 eligible included studies 
Outcomes - 
Efficacy 
1) All VTE: Extended Thromboprophylaxis 
significantly reduced incidence of all VTE 
compared to conventional 
thromboprophylaxis (2.6% v 5.6% Risk 
Ratio (RR) 0.44 Confidence Interval (CI) 
1) Symptomatic DVT: none had 
analysable data 
2) Asymptomatic DVT: only one 
study with sufficient follow up rate – 
statistically significant difference at 
four weeks postop 
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0.28-0.70, Number needed to treat (NNT) 
39) 
2) Proximal DVT: Incidence significantly 
lower in Extended Thromboprophylaxis 
group (1.4% v 2.8% CI 0.23-0.91, NNT 71) 
3) Distal DVT: results did not reach 
statistical significance 
4) PE: No statistically significant difference 
between PE incidence in the two groups 
3) PE: only reported in one study, 
insufficient follow up rate for criteria 
Outcomes - 
safety 
1) Major Bleeding: No statistically significant 
difference observed 
2) All-Cause Mortality: Overall mortality 
similar 4.2% v 3.6% RR 0.79 CI 0.47-1.33 
NNT 167 
1) All-cause mortality: only reported 
in one study, with no statistically 
significant difference at three or 
twelve months. 
2) Bleeding: only reported in one 
study – no statistically significant 
difference at four weeks or three 
months postoperatively for either 
major or minor bleeding 
Conclusions Extended Thromboprophylaxis significantly 
reduces the overall incidence of VTE and 
proximal DVT without increasing the risk of 
major bleeding. 
There is limited and low-quality 
evidence that extended duration low 
molecular weight heparin for 
perioperative thromboprophylaxis 
reduces DVT in patients with cancer 
undergoing major abdominal or 
pelvic surgery. 
More and better-quality evidence is 





- Only 3 Randomized controlled trials 
identified 
- Heterogeneity from inclusion of different 
types of surgeries, two studies allowed 
inclusion laparoscopic interventions 
- Insufficient data on specific cancer types 
and stages; consequently, individualized 
recommendations cannot be derived from 
data 
- Open label nature of some included 
studies; associated bias in patient symptom 
reporting and physician suspicion of VTE  
- Restriction of electronic search 
strategy to patients with cancer 
(potential missed studies with 
subgroups of cancer patients) 
- Limited number and low quality of 
included studies (included small 
sample size, high loss to follow up, 
focus on asymptomatic DVT) 
Strengths of 
Review 
- Comprehensive search 
- Inclusion all major prospective studies to 
date assessing ETP after major abdominal 
and pelvic cancer surgery 
- All VTE objectively diagnosed 
- Outcomes between studies reasonably 
similar 
- Low statistical heterogeneity 
- Use of Cochrane collaboration 
methodology 
- Priori definition of outcomes 
- GRADE approach to evaluate 




Of the 18 included articles, only four directly compared inpatient and extended duration VTE 
prophylaxis making them suitable for statistical analysis. These were Schomburg et al32, Samama et 
al33, Holwell et al34 and Kakkar et al35. Furthermore, the only outcome consistently reported across all 
four of these studies was total VTE rate. Kakkar and Samama both reported DVT rate as a subgroup of 
VTE. Three (Kakkar, Samama and Schomburg) reported bleeding complications, however only Kakkar 
and Samama further reported subgroups of critical and fatal bleeding. 
 
Regarding the primary outcome of VTE events, there was a non-significant risk reduction (risk ratio 
1.55, CI 0.81-2.95) in total VTE rate. Moderate heterogeneity between the studies included in the 
assessment of total VTE rate was observed (I2=59%). This is illustrated by Figure 3. No subgroups 




Figure 3: Forest plot illustrating direct comparison of total VTE rate 
 
The only secondary outcome assessed across more than one of the direct comparison articles was the 
total rate of any bleeding complication, in Kakkar, Samama and Schomburg32,33,35. This result was also 
non-significant (P=0.43) and there was a larger degree of heterogeneity (I2= 72%) seen between the 





Figure 4: Forest plot illustrating direct comparison of bleeding events (any) 
 
While additional outcomes including DVT rate, bleeding in a critical organ and fatal bleeding were 
covered by both the results in Kakkar and Samama, we did not feel it was appropriate to directly 
compare two papers only. 
 
Of the remaining eleven included articles, eight reported outcomes relevant to the efficacy of heparin 
VTE prophylaxis while one reported outcomes relevant to the safety of heparin use as VTE prophylaxis 
in patients following open abdominal or pelvic surgery for malignancy. Two reported both efficacy and 
safety outcomes. None directly compared inpatient and extended duration prophylaxis. 
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Once again, the only efficacy outcome that was consistently reported across included studies was total 
VTE rate. Some studies did analyse subgroups of DVT versus PE rates and symptomatic versus 
asymptomatic VTE. Chandra et al36, Sanderson et al37, Mohn et al38 and Varpe et al39 all published 
cohort studies on the efficacy of inpatient heparin VTE prophylaxis following Colorectal procedures, 
with all reporting low VTE rates in these patients with a range between 0.6%39 to 1.35%38. While these 
papers were comparable not only in their population (colorectal cancer patients) and length of follow up 
(one to three months), all were limited by a small sample size. 
 
Klimowicz et al40, Sun et al41, Jeong et al42, and Beyer et al43 also all included a cohort of patients 
receiving inpatient heparin, with comparisons made to mechanical prophylaxis, no prophylaxis, as well 
as comparison to therapeutic enoxaparin in Schmitges44 et al and warfarin anticoagulation by Sun et 
al41. 
 
Both Yang et al45 and Sakon et al46 reported the addition of inpatient pharmacological prophylaxis to 
reduce the risk of VTE compared to mechanical only prophylaxis (0.72% compared to 0.91% (Yang45) 
and 1.2% compared to 19.4% (Sakon46)). The large difference in VTE rate reported in Sakon46 could be 
attributed to its broad inclusion criteria for operative type – including any laparotomy with curative intent 
for a malignancy, whereas Yang included only colorectal cancer patients.  
One study - Beyer et al43 included subgroups of asymptomatic and symptomatic DVT, reporting 
extremely high rates of asymptomatic VTE at both day 8 (96.5%) and day 21 (88.7%) postoperatively.  
 
Regarding safety, only Sakon et al46, Jeong et al42 and Schmitges et al44 reported safety outcomes 
associated with postoperative heparin VTE prophylaxis. Sakon et al46 and Jiong et al42 compared 
inpatient heparin with mechanical only or no prophylaxis, while Schmitges et al44, compared four weeks 
of therapeutic dose heparin (60+mg enoxaparin) with four weeks of prophylactic dose heparin (40mg 
enoxaparin subcutaneously daily).  
 
Unsurprisingly Sakon46 and Jiong42 both report total bleeding events to be greater in patients receiving 
pharmacological prophylaxis (total bleeding complication rates of 9.17% and 13.4% in patients 
receiving heparin compared to 7.89% and 5.5% in those receiving mechanical and no prophylaxis). 
Sakon46 also reported major bleeding events (defined as death, transfusion of more than two units of 
red cells, haemoglobin drop of more than 2g/dL, or retroperitoneal, intracranial or intraocular bleeding 
resulting in serious or life-threatening events) occur at a rate of 4.6% compared to 2.6% in those 
patients receiving mechanical prophylaxis with inpatient pneumatic compression alone. 
Likewise, reported transfusion rates were lower when mechanical prophylaxis alone was used 
compared to those patients receiving additional pharmacological prophylaxis42,43. 
 
In summary, analysis of the included studies did not identify any statistically significant reduction in 
postoperative VTE risk associated with extended duration use of heparin VTE prophylaxis compared to 
inpatient only duration prophylaxis. Nor was any statistically significant difference in rates of bleeding 
complications identified between the two groups. However, multiple smaller cohort studies not suitable 
for inclusion in statistical analysis report lower rates of postoperative VTE in patients receiving 
extended duration pharmacological prophylaxis, albeit with an increased risk of bleeding complications 
and transfusion requirement. 
 
DISCUSSION:  
Overall, literature review of recently published papers (<10 years old) exposes a surprisingly low level 
of poor-quality evidence for extended pharmacological VTE prophylaxis. 
 
Two pre-existing systematic reviews were identified, however only one study47 is included in both.  
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These are interesting to compare to the outcome of our study in that their outcomes are almost directly 
contradictory – while Fagaranasu et al30 concludes that “extended thromboembolism prophylaxis 
significantly reduces the overall incidence of VTE and proximal DVT without increasing the risk of major 
bleeding”, Akl et al31 is more consistent with our own results reporting “limited and low quality evidence 
that extended duration LMWH for perioperative thromboprophylaxis reduces DVT in patients with 
cancer undergoing major abdominal or pelvic surgery” concluding that “more and better quality 
evidence is needed to justify extended regimes”. Criticisms of the Fagaranasu review which may 
explain its conflicting outcome include the comparison of laparoscopic and open studies (i.e. dissimilar 
populations) and invitation of bias by including observational studies as well as randomised controlled 
trials. 
 
It is also interesting to note the number of narrative reviews that we excluded on full text review. It is 
possible this volume of narrative reviews reflects other prior attempts to perform systematic review and 
meta-analysis in this area, where the poor level of evidence available precluded systematic review from 
being conducted. 
 
A limited number of papers were appropriate for direct comparison, and these results must be 
interpreted with caution due to the small number of studies included, small sample sizes in some 
studies, and significant degree of heterogeneity observed between included studies. In addition, the 
population of the Samama et al33 study was much larger than that of the other included studies and so 
the combined results need to be interpreted with an awareness of the impact of this on the overall 
outcome.  
Allowing for this, our analysis found no significant difference in postoperative VTE rates or 
postoperative bleeding complication in patients receiving extended duration prophylaxis compared to 
those receiving inpatient duration prophylaxis.  
 
However, on narrative review of the remaining literature unsuitable for direct comparison, many studies 
did observe cohorts receiving extended duration pharmacological prophylaxis to have lower rates of 
postoperative VTE, and an increased rate of bleeding complications and number of blood transfusions.  
 
Across all included studies, total rates of VTE events that were sufficiently symptomatic as to trigger 
investigation and objective confirmation of diagnosis by imaging were generally low. This may imply 
that clinically significant postoperative VTE is a rarer complication than many clinicians believe. 
Assuming this were true, extrapolation would suggest that while pharmacological prophylaxis with 
heparin may convey a benefit, this benefit is likely small and thus the number needed to treat (NNT) 
would be high, therefore leading to a high cost of prophylaxis at a population level despite the individual 
cost being low. Thus, Kakkar had only 2 patients in the extended group and 3 in the inpatient group that 
developed a PE35. Samama had 5 in the extended group and 10 in the inpatient group33. Combining the 
2 extended populations one could conclude that extending VTE prophylaxis results in 6 fewer PE’s for a 
total 2620 patients who received extended prophylaxis. Given the small number of studies and small 
sample sizes of the articles included in our direct comparison, it is possible that a benefit does exist, 
and the comparison was simply underpowered to confirm this. If this is true it is possible that the 
benefits of pharmacological VTE prophylaxis in reducing postoperative VTE may in fact be outweighed 
by the financial cost of treatment and or potential complications associated with its use. A cost benefit 
analysis was beyond the scope of the present study. 
 
In contrast, when asymptomatic VTE was considered, this appears to have an extremely high 
prevalence postoperatively, with some studies reporting up to 96.5% on day 8 and 88.7% day 21 
postoperatively43. If this is assumed to be true, with a prevalence this high it would appear unlikely it 
carries any truly significant implication on overall patient outcome, and raises the question if it is 
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possible asymptomatic DVT falls within the spectrum of normal physiology following a traumatic insult 
to the body such as major surgical intervention in the abdomen or pelvis.  
 
This outcome, while unexpected does raise important questions. Firstly, use of pharmacological VTE 
prophylaxis is established practice worldwide, and while there is a lack of consistency between type 
and duration of prophylaxis used by individual providers and centres, extended duration is becoming 
extremely common. In failing to identify any significant reduction in VTE risk associated with extended 
duration prophylaxis, we must wonder how this became an established and widely accepted part of 
clinical practice without a truly strong evidence base. 
 
While there is certainly evidence for its use in other specialties47, it is uncertain to what extent it is 
appropriate to apply evidence from other specialties such as orthopaedics to patients undergoing pelvic 
surgery. While patient characteristics are likely to have commonalities across both specialties, vastly 
different operative characteristics and the presence or absence of malignancy in the patient result in a 
significant difference between the populations. 
 
Limitations of our study included the small number of identified studies suitable for analysis and the 
small sample sizes of included articles. This could be improved by extending the time period used in 
the study’s inclusion criteria to include articles older than ten years. In addition, due to the limited 
number of suitable articles identified, some included papers do include some data not exclusively from 
patients undergoing open surgery.  
 
CONCLUSION: In conclusion, our study found no significant difference in postoperative VTE rates or 
bleeding complications in patients receiving extended duration heparin VTE prophylaxis compared to 
those receiving inpatient prophylaxis after open abdominopelvic surgery for malignancy. However, the 
available evidence was limited and of poor quality so this finding must be interpreted with caution.  
 
This result raises the important question of how the use of extended duration prophylaxis in this 
population has become widespread, common practice without a truly strong evidence base proving a 
benefit. If this is truly the case, we question whether current recommendations regarding its use should 
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INTRODUCTION AND OBJECTIVES: 
Extended Venous Thromboembolism (VTE) Prophylaxis is recommended as best practice following 
major open abdominopelvic surgery for malignancy. However, the financial implications of post-
operative enoxaparin use in this setting have escaped scrutiny. We aim to compare the cost of 
providing this prophylaxis with that of predicted VTE events without prophylaxis. 
 
MATERIALS/METHODS: 
We previously published a literature review and meta-analysis comparing inpatient versus extended 
duration enoxaparin VTE prophylaxis in patients undergoing open abdominopelvic surgery for 
malignancy. In this paper we compare these results to literature estimates of the incidence of VTE, and 
the current cost of Enoxaparin on the Pharmaceutical benefits scheme. 
 
RESULTS: 
The risk of VTE after major surgery is estimated as between 0.8-6.2%, and cost of a standard 40 mg 
prophylactic dose of enoxaparin is $4.951. Therefore, the cost of preventing one Venous 
Thromboembolism can be estimated as being between $1116-$8522 using two weeks of prophylaxis, 
or between $17045-$23437 if four weeks of prophylaxis are used. The observed rate of VTE in the 
literature population was 1.63% despite this population having received extended prophylaxis. 
 
CONCLUSIONS: 
Our analysis suggests that providing extended duration postoperative VTE prophylaxis to patients 
following open abdominopelvic procedures for malignancy is financially justifiable, with a lower total 
cost than that of treating predicted VTE events in this population without prophylaxis. However, 
considering prior findings of no significant benefit in VTE reduction in patients of receiving extended 
duration over inpatient only prophylaxis, inpatient only duration prophylaxis may still be a more efficient 





















INTRODUCTION AND OBJECTIVES: 
Extended Venous Thromboembolism (VTE) prophylaxis following major open abdominopelvic surgery 
for malignancy is recommended as best practice1,2. However currently available guidelines do not 
quantify an exact recommended duration of prophylaxis, nor have the financial implications of post-
operative prophylactic enoxaparin use been scrutinised in depth. We aim to compare the cost of 
providing this prophylaxis with that of VTE events without prophylaxis.  
 
METHODS: 
We previously designed and conducted a literature review and meta-analysis comparing inpatient 
versus extended duration VTE prophylaxis in patients undergoing major open abdominopelvic surgery 
for malignancy49. The results of this review were then compared with literature estimates of the 
incidence of VTE events in the absence of pharmacological prophylaxis and current cost of Enoxaparin 
on the Pharmaceutical Benefits Scheme (PBS)50 in Australia. Using this data we calculated the cost of 
providing both two and four week duration extended duration prophylaxis to the overall population 
described within the literature, as well as the predicted/estimated cost of the VTE events observed in 
these populations. 
Assumptions made in making these calculations include that all patients were compliant with treatment 
and received a standard prophylactic dose of enoxaparin, and did not receive any additional 
pharmacological thromboprophylactic agents or were otherwise anticoagulated. 
Ethical approval was not required given no patients were directly involved in the study, with results 
based off literature review. 
 
RESULTS: 
The previous literature review identified a total of four articles directly comparing inpatient and extended 
duration VTE prophylaxis suitable for statistical analysis. Within these four articles a total population of 
2705 patients received extended duration prophylaxis, with 44 VTE events observed in these 2705 
patients despite them receiving prophylaxis. In the safety arms of the included studies, of 2754 patients 
being evaluated for bleeding complications associated with extended duration prophylaxis, 53 had a 
bleeding event potentially attributable to use of prophylaxis49.  
 
A standard prophylactic dose of enoxaparin prior to any adjustments for renal function or extremes of 
weight is 40mg injected subcutaneously once per day. The Pharmaceutical Benefits Scheme lists the 
dispensed price for maximum quantity of 40 mg enoxaparin as $99.02 for 20 syringes of 40 mg/0.4 ml 
enoxaparin sodium, so the cost of each 40 mg dose of enoxaparin is $4.951 ($99.02/20)50. Therefore 
providing 2 weeks of extended Venous Thromboembolism prophylaxis costs the healthcare system 
$69.314 ($4.951 x 14) per patient and 4 weeks of extended Venous Thromboembolism prophylaxis 
costs $138.628 ($4.951 x 28) per patient.  
 
The risk of a Venous Thromboembolism event following major surgery is variably estimated between 
0.8– 6.2%51 which is equivalent to between 22 and 168 people in the overall literature population of 
2705. With providing prophylaxis to the population of 2705 patients costing a total of $187 494.37 for 
two weeks or $374988.74 for four weeks, the cost of preventing one venous thromboembolism can be 
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estimated as between $8522 (187494.37/22) and $1116($187494.37/168) using two weeks prophylaxis 
or between $17044.9421 (374988.74/22) and $23436.7962 (374988.74/168) with four weeks 
prophylaxis. The calculations of this are summarised mathematically below 
 
Predicted risk of VTE in study population (2705) = 22 to 168 people: 
2705 x 0.8% = 21.64 (22)  
2705 x 6.2% =167.71 (168) 
 
Total cost of prophylaxis 
a) 2 weeks: $69.314 x 2705 = $187 494.37  
b) 4 weeks: $138.628 x 2705 = $374988.74  
 
Therefore, to prevent one VTE: 
a) With two weeks prophylaxis  
$187494.37  22 = $8522 AND $187494.37  168 = $1116  
b) With four weeks prophylaxis  
$374988.72  22 = $17044 AND $374988.72  168 =$2232 
 
Therefore, with the cost of a single VTE event estimated at $4090 USD51 giving an adjusted cost 
accounting for inflation of $5987.14 USD in 2020, equivalent to $8222.97 AUD using 6/9/2020 
exchange rates, the VTE rate would need to be at least 0.83% (8522/8222.97=1.03 and 1.03x0.8=0.83) 
to be equal or greater to the cost of providing extended prophylaxis for 2 weeks, or 1.66% 
(17044/8222.97=2.07and 2.07x0.8=1.66) to be equal or greater to the cost of providing extended 
prophylaxis for 4 weeks. These calculations are summarised mathematically below 
 
a) Two weeks: 
$8522  8222.97 = 1.03 
1.03 x 0.8 = 0.83 
 
b) Four weeks: 
$17044  8222.97 = 2.07 
2.07 x 0.8 = 1.66 
 
The observed rate of VTE in the literature population was 44/2705 (1.63%)49, with an estimated cost to 




In a healthcare environment with ultimately limited resources, there is ever increasing awareness of the 
need to consider the financial and economic impact of treatments at a population level in addition to 
their clinical indication for the individual. Ensuring the benefit of a treatment is not outweighed by the 
cost of providing it helps to ensure efficient use of resources to maximise the population benefit. 
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The initial introduction of VTE prophylaxis to select patient populations showed a clear benefit to these 
individuals resulting in rapid widespread uptake of its use and extrapolation to include other patient 
populations. Duration of use was later extended in recognition of the potential for VTE to be a delayed 
postoperative complication. However, guidelines remain nonspecific about the exact timeframe this risk 
and recommendation for prophylaxis persists, resulting in significant variability between individual 
providers and institutions. This is likely in part due to limited recent evidence specifically regarding 
extended duration prophylaxis use in specific and contemporary patient populations. In addition, many 
aspects of surgical technique and hospital admissions have changed since the initial research 
demonstrating efficacy of Enoxaparin prophylaxis. 
 
Our finding that a VTE rate of 0.83% or 1.66% is required to achieve cost neutrality respectively for two 
and four weeks of prophylaxis supports the financial justifiability of extended VTE prophylaxis using 
either two or four weeks of enoxaparin, falling in the lower end of the range of predicted VTE rates 
without prophylaxis. In addition, the observed VTE rate of 1.63% within the literature population, despite 
this population’s use of extended prophylaxis, falls not only within the predicted VTE rate without 
prophylaxis, but is greater than the VTE rate required for cost efficiency of two weeks prophylaxis and 
almost equal to that required for cost efficiency with four weeks prophylaxis. This not only further 
supports the financial justifiability of providing two weeks prophylaxis, but as this was observed in a 
population already receiving extended duration VTE prophylaxis, leads us to suspect the true VTE rate 
without prophylaxis to fall on the higher end of prior literature estimates, further increases the likelihood 
of four weeks duration prophylaxis also being financially justifiable. 
 
However, our prior literature review did not identify any significant efficacy benefit in preventing VTE 
events to be associated with extended duration prophylaxis when compared with inpatient only duration 
prophylaxis in contemporary literature. Interpreting our findings on cost analysis in this context is 
challenging as while it appears provision of extended prophylaxis is justifiable with a lesser cost than 
that of managing predicted VTE events in this population without prophylaxis, if the overall reduction in 
VTE events by use of extended prophylaxis is insignificant compared to that with inpatient only 
prophylaxis, inpatient only duration would appear to be economically superior by incurring significantly 
less costs to provide an essentially equivalent benefit. 
 
In applying these findings to a clinical context non-financial costs must also be considered. It is difficult 
to imagine healthcare providers being willing to place individual patients they manage at risk of a 
potentially catastrophic VTE event on the basis of providing a relatively intangible financial benefit to 
the greater population. Financial costs may also be perceived by individuals to be of insignificant 
importance when compared to the impact of decline in health and function on overall quality of life. 
Consequently, even with some evidence that inpatient duration prophylaxis provides a similar benefit in 
VTE reduction compared to extended duration for far lesser costs, while there remains no definite 
evidence of extended duration prophylaxis being directly harmful to the individual, it is likely providers 
will continue to provide extended duration prophylaxis to the individual patients in their care.  
 
Limitations of this study include bias from using a patient population obtained via literature review, 
resulting in the inclusion of any pre-existing biases in the included papers. In particular the literature 
review identified only a small number of studies suitable for analysis, all but one of which had small 
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sample sizes, meaning the one paper with a larger sample size may have disproportionately skewed 
the results. This is difficult to eliminate without performing our own study and data collection on a novel 
population of patients which is outside the scope of this study. In addition, this analysis did not include 
analysis costs incurred from treatment of bleeding complications associated with use of VTE 
prophylaxis. However, our prior literature review again did not identify any significant difference in rate 
of bleeding complications between patients receiving inpatient duration prophylaxis compared to those 
receiving extended duration prophylaxis, making it unlikely this would result in a significant change to 
the outcome of cost analysis. 
 
In future, it would be ideal to develop a multi-institutional, prospective database of patients receiving 
postoperative VTE prophylaxis documenting the duration of treatment, VTE and bleeding events and 
comprehensive details of treatments provided for these to enable further direct large-scale comparison 
of these events and their financial implications in the context of prophylaxis. This would however be 
resource intensive and time consuming making it again outside the scope of this study. 
 
CONCLUSION: 
In conclusion, our analysis suggests that providing extended duration postoperative VTE prophylaxis to 
patients following open abdominopelvic procedures for malignancy is financially justifiable, with a lower 
total cost than that of treating predicted VTE events in this population without prophylaxis. However, 
considering prior findings of no significant benefit in VTE reduction in patients of receiving extended 
duration over inpatient only prophylaxis, inpatient only duration prophylaxis may still be a more efficient 
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In conclusion, the project had three major findings.  
 
Firstly, and perhaps the most significant finding, was the unexpected discovery that despite the fact that 
extended VTE prophylaxis with heparin is already an accepted and widely used treatment, there is only 
a small volume of contemporary literature (published within the last ten years) available directly 
investigating the impact of duration of VTE prophylaxis in patients undergoing abdominopelvic surgery 
for malignancy. In addition, what literature was available was of poor quality, limiting the confidence 
with which conclusions can be drawn from it and applied to clinical use. 
If these limitations are accepted, the second major finding of the study was that we found no significant 
difference in either efficacy or safety of inpatient versus extended duration use of pharmacological VTE 
prophylaxis with heparins following major open abdominopelvic surgery for malignancy.  
The third major finding was that when assessed on a purely financial basis we found provision of 
extended duration VTE prophylaxis using heparin to be likely justifiable, with a lesser cost than that of 
treating predicted VTE events in the absence of prophylaxis. This finding applied to both two week and 
four-week durations of use of extended prophylaxis. 
 
Detailed discussion of these findings is included in each relevant publication and in accordance with 
The University of Adelaide theses specification guidelines these discussions will not be reworked here. 
 
Problems encountered over the course of the project were primarily related to the unexpectedly small 
volume and poor quality of contemporary literature identified on systematic review. This meant it was 
not possible to answer all of the questions described in the protocol, and precluded subgroup analysis 
as was initially planned. While the initial decision to limit included papers to those published within the 
last ten years was made with the intent to ensure the literature populations were likely to closely 
resemble contemporary patient populations, it is likely that this decision significantly contributed to this 
problem by excluding larger and better-quality earlier studies. In addition, had a larger time period of 
publications been assessed, the inclusion of earlier publications may have benefited our study by 
potentially capturing a larger population of patients specifically undergoing open surgery given the use 
of laparoscopic, robotic and other minimally invasive techniques has increased over time, thus reducing 
the proportion of open cases being performed. 
 
Immediate future directions for the project include publication of the final cost analysis paper pending 
the outcome of peer review. Further possible future directions could include addressing the problems 
described above by repeating the project with expansion of inclusion criteria to include earlier 
publications. An alternative, ideal solution to address this and definitively answer the question of 
optimum prophylaxis duration would be to develop a randomised controlled trial of inpatient versus 
varying extended duration VTE prophylaxis in a population of patients undergoing major open 
abdominopelvic surgery for malignancy. This would however likely be complex and extremely time 
consuming, requiring ethical approval, involvement of a large number of hospitals and clinicians in 
order to generate sufficient patient numbers to reach statistical significance, and potentially use of 
placebo extended prophylaxis (for example subcutaneous injection of sterile normal saline to mimic 
enoxaparin) in some patients to enable blinding. A more practical alternative could be the development 
of a national prospective database registry of patients undergoing VTE prophylaxis collecting data on 
operative procedure, type and duration of prophylaxis and incidence of VTE and bleeding events. This 
would again require ethical approval, cooperation of a large number of hospitals and clinicians, 
however could in future enable analysis of a large, population level cohort study and or analysis of 
subgroups within this population. 
 
Overall, the major contributions of the project’s findings to current knowledge are the discovery that the 
recent evidence for use of extended VTE prophylaxis in patients undergoing open abdominopelvic 
surgery for malignancy may not be as strong as it is perceived to be, and what recent evidence exists 
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does not demonstrate a significant difference in efficacy or safety of extended duration prophylaxis as 
compared to inpatient only duration. These findings should encourage both clinicians and researchers 
to not only to critically evaluate and re-examine their own practices and rationale in providing 
postoperative VTE prophylaxis, but also to continually critically reappraise all treatments and 
procedures, as simply being established practice or widely used does not necessarily guarantee there 
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